Araştırma Çıktıları | Scopus

Permanent URI for this community

http://hdl.handle.net/20.500.14701/26769

Browse

Browsing by Author "Abadoglu O."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Prevalence of asthmatic smokers: Turkish experience (PASTE Study)
    (Blackwell Publishing Ltd, 2014) Yildiz F.; Dursun A.B.; Disçi R.; Abadoglu O.; Atalay F.; Ates G.; Buyukoglan H.; Ceyhan B.; Ceylan E.; Deveci F.; Ediger D.; Ekici A.; Erdinc M.; Gemicioglu B.; Goktalay T.; Meral M.; Mungan D.; Ogus C.; Ozge C.
    Background: Although both asthma and smoking are major health problems worldwide, smokers are often excluded from asthma studies. Objectives: It was aimed to verify the prevalence of asthmatic smokers in Turkey and assess the effects of smoking based on clinical parameters, exacerbations and hospitalizations because of lack of national data about the prevalence of smoking among asthmatics. Methods: The study protocol was comprised of a retrospective questionnaire. The asthmatic patients were followed in the outpatient clinics of 18 tertiary hospitals selected from seven different geographical regions in Turkey. We evaluated demographic data, smoking habits, asthma-related diseases, respiratory function and emergency visits. Results: The study population included 1385 patients (M/F: 343/1042), and the mean age was 45.1±14.0 years. Current and former smoking prevalence was 11.4% and 15.1%, respectively. Smoker rates were higher in males and younger asthmatics compared with females and older asthmatics (P<0.01 and P<0.05, respectively). Smoking history ranged from 0.20 to 90 pack-years (the mean was 12.9), and smokers had a higher level of education compared with nonsmokers (P<0.01). Socioeconomically, the most developed region had the highest rate of smoker asthmatics (33.9%; P=0.014). There was an increase in the number of exacerbations in smoker asthmatics during the previous year, but it was not statistically significant (P>0.05). Conclusion: We showed that the smoking prevalence in Turkey was lower in asthmatics (11.4%) compared with the general population (44.5%). Nevertheless, every effort should be made to encourage asthmatics to stop smoking because smoking is a modifiable risk factor for adverse asthma health outcomes. © 2013 John Wiley and Sons Ltd.
  • No Thumbnail Available
    Item
    Picturing asthma in Turkey: results from the Turkish adult asthma registry
    (Taylor and Francis Ltd., 2023) Celik G.E.; Aydin O.; Gokmen D.; Koycu Buhari G.; Celebi Sozener Z.; Gemicioglu B.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Koca Kalkan I.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Oner Erkekol F.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Oguzulgen I.K.; Basyigit I.; Baris S.A.; Yilmazel Ucar E.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Turk M.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Polat Yulug D.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Tas Gulen S.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Arslan B.; Cetin G.P.; Soyyigit S.; Kara B.Y.; Pasaoglu Karakis G.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Sevinc C.; Omeroglu Simsek G.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.
    Introduction: National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry for patients with asthma aiming to take a snapshot of our patients, thereby assigning the unmet needs and niche areas of intervention. Methods: Case entries were performed between March 2018 and March 2022. A web-based application was used to record data. Study outcomes were demographic features, disease characteristics, asthma control levels, and phenotypes. Results: The registry included 2053 patients from 36 study centers in Turkey. Female subjects dominated the group (n = 1535, 74.8%). The majority of the patients had allergic (n = 1158, 65.3%) and eosinophilic (n = 1174, 57.2%) asthma. Six hundred nineteen (32.2%) of the patients had obese asthma. Severe asthma existed in 670 (32.6%) patients. Majority of cases were on step 3–5 treatment (n: 1525; 88.1%). Uncontrolled asthma was associated with low educational level, severe asthma attacks in the last year, low FEV1, existence of chronic rhinosinusitis and living in particular regions. Conclusion: The picture of this registry showed a dominancy of middle-aged obese women with moderate-to-severe asthma. We also determined particular strategic targets such as low educational level, severe asthma attacks, low FEV1, and chronic rhinosinusitis to decrease uncontrolled asthma in our country. Moreover, some regional strategies may also be needed as uncontrolled asthma is higher in certain regions. We believe that these data will guide authorities to reestablish national asthma programs to improve asthma service delivery. © 2023 Taylor & Francis Group, LLC.
  • No Thumbnail Available
    Item
    Socioeconomic status has direct impact on asthma control: Turkish adult asthma registry
    (John Wiley and Sons Inc, 2025) Arslan B.; Türk M.; Hayme S.; Aydin Ö.; Gokmen D.; Buhari G.K.; Sozener Z.C.; Gemicioglu B.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Kalkan I.K.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Erkekol F.O.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Oguzulgen I.K.; Basyigit I.; Baris S.A.; Ucar E.Y.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Yulug D.P.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Cetin G.P.; Soyyigit S.; Kara B.Y.; Karakis G.P.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Sevinc C.; Simsek G.O.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Celik G.E.; Uysal M.A.
    Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma-related death. Objective: In this study, we aimed to determine socioeconomic levels of asthmatic patients according to a national database and investigate the effects of social markers on disease control in our region. Methods: This is an analysis of data from 2053 adult asthma patients from a multicentre chart study in Turkey. Socioeconomic status (SES) data were collected from questionnaires and this form was sent to the patients via e-mail. Parameters related to social status and poor disease control were analyzed. Results: Illiteracy (OR:2.687 [95% CI: 1.235–5.848]; p = 0.013) and lower household income (OR:1,76 [95% CI: 1.002–3.09]; p = 0.049) were found as independent risk factors for hospitalization in the multivariate logistic regression analysis. Therewithal, being aged between 40 and 60 (OR: 1.435 [95% CI: 1.074–1.917]; p = 0.015), illiteracy (OR: 2.188 [95% CI: 1.262–3.795]; p = 0.005) and being employed (OR: 1.466 [95% CI: 1.085–1.847]; p = 0.011) were considered as independent risk factors for systemic corticosteroid use at least 3 days within last 1 year. Conclusion: As a result of our national database, education level, household income and working status briefly socioeconomic status have impacts on asthma control. Identification of social markers in asthma and better recognition of risk factors based on the population gives us clues to provide better asthma control in the future. © 2025 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
  • No Thumbnail Available
    Item
    Asthma patients with obesity have a unique phenotype: a subanalysis of the Turkish adult asthma registry
    (Taylor and Francis Ltd., 2025) Celebi Sozener Z.; Oguzulgen I.K.; Ozalp Ates F.S.; Baccioglu A.; Argun Barıs S.; Ediger D.; Gunaydın F.E.; Sevinc C.; Seker U.; Yılmaz Kara B.; Beyaz S.; Mungan D.; Aydin O.; Gokmen D.; Buhari G.K.; Gemicioglu B.; Bulut I.; Orcen C.; Kepil Ozdemir S.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Alan Yalim S.; Yilmaz I.; Koca Kalkan I.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Akkor Gelincik A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Oner Erkekol F.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Basyigit I.; Yilmazel Ucar E.; Erdogan T.; Polatli M.; Turk M.; Pur L.; Yegin Katran Z.; Sekibag Y.; Aykac E.F.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Polat Yulug D.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Arslan B.; Cetin G.P.; Soyyigit S.; Pasaoglu Karakis G.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Omeroglu Simsek G.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Cadalli Tatar E.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Celik G.E.
    Objective: The obese-asthma phenotype has gradually increased in the last few years. We aimed to assess the differences between obese and non-obese patients with asthma. Methods: This research is a subanalysis of the Turkish Adult Asthma Registry (TAAR). Clinical presentation, disease control, severity, and demographics of obese and non-obese (normal-weight, overweight) patients were compared. Results: The obesity rate in TAAR was 32.2% (n = 619/1919; 18-83 years; 527 F/92 M). Patients with asthma and obesity had higher rates of childhood obesity, longer symptom duration, later onset of asthma, and more severe asthma. These patients were more likely to be female, older, less educated, and live in rural areas. Patients with obesity had more scheduled visits and emergency visits compared with non-obese patients, but similar asthma control, oral corticosteroid use, hospitalizations, intensive care unit admissions, and unscheduled visits. They also had a higher frequency of T2-high but lower frequency of possible T2-low phenotypes compared with normal-weight asthmatics. The risk of severe asthma in patients with obesity was 6.04 times higher for allergic than non-allergic patients and 3.58 times higher for the T2-high phenotype than for possible T2-low phenotypes. A one-unit increase in the asthma control test reduced the risk of severe asthma by 22%. Conclusions: A good definition of this phenotype is important to ensure that appropriate treatment strategies are implemented to achieve the control goal. We also believe that prevention of childhood obesity is an effective and pivotal strategy to achieve the goal of asthma control. © 2025 Taylor & Francis Group, LLC.
  • No Thumbnail Available
    Item
    Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry
    (W.B. Saunders Ltd, 2025) Gemicioglu B.; Gokmen D.; Can A.; Sevinc C.; Oguzulgen I.K.; Soyyigit S.; Yakut T.; Havlucu Y.; Aydin O.; Buhari G.K.; Sozener Z.C.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Kalkan I.K.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Erkekol F.O.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Basyigit I.; Baris S.A.; Ucar E.Y.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Turk M.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Yulug D.P.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Donmez H.; Arslan B.; Cetin G.P.; Kara B.Y.; Dursun A.B.; Karakis G.P.; Kendirlinan R.; Ozturk A.B.; Simsek G.O.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Çelik G.E.
    Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians’ preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics. Patients’ characteristics and disease profiles were analyzed to identify factors associated with the prescription of add-on LAMA across the entire cohort. A comparative analysis was performed among three groups: MART (ICS/formoterol as a maintenance and reliever therapy) plus LAMA, Conventional (ICS/LABA as a maintenance and short-acting beta agonist as reliever) plus LAMA and Triple (ICS/LABA/LAMA single inhaler). LAMAs were added to ICS/LABA in 11.7 % of patients in the national registry. Logistic regression analysis revealed that older age, low FEV1 (%), Asthma Control Test (ACT) scores less than 20, and severe exacerbation were the main factors influencing the initiation of LAMA in our registry. However, demographic characteristics of asthma, control status, pulmonary function test results were similar among the three groups of LAMA users (p > 0.05). Physicians used LAMAs without phenotyping based on allergic status or eosinophil levels (p > 0.05). Mepolizumab was added after LAMA in all patients, while omalizumab was initiated before LAMA in 16.9 % of the patients receiving LAMA along with biologics. Add-on LAMAs were predominantly prescribed for older, uncontrolled, and exacerbated asthma patients with low FEV1. © 2024 Elsevier Ltd